Purdue University College of Pharmacy and NorthStar Medical Radioisotopes Announce Collaborative Agreement Expanding Nuclear Pharmacy Training Curriculum

Beloit, Wis. and W. Lafayette, Ind., August 20, 2019 – NorthStar Medical Radioisotopes, LLC and Purdue University’s College of Pharmacy today announced a collaborative agreement to expand the College’s nuclear pharmacy training curriculum. The agreement includes the addition of an automated isotope separation system developed by NorthStar, the RadioGenix System, to the College’s nuclear pharmacy curriculum. Purdue College of Pharmacy students will have the opportunity to gain hands-on experience with the RadioGenix System at the College’s state-of-the-art pharmacy education facility, the Porteus Center. The agreement also includes an opportunity for Purdue College of Pharmacy students to provide feedback about the RadioGenix System and early testing of planned enhancements.

“We are extremely grateful for our partnership with NorthStar,” said Eric L. Barker, Ph.D. Dean, Purdue College of Pharmacy. “The addition of the RadioGenix System will give our students unparalleled hands-on experience with the latest advancements in radiopharmacy production techniques and is well-equipped for the professional workplace.”

“We have collaborated with NorthStar on several projects over the last few years, and we are excited to be given the opportunity to work closely with them in advancing our educational programming,” said Dr. Mark J. Grondahl, Director of the Nuclear Pharmacy Program at Purdue. “We look forward to further strengthening our collaboration with NorthStar in the future.”

“We are excited to collaborate with Purdue University’s prestigious College of Pharmacy in advancing educational programming related to the latest advancements in nuclear medicine and radiopharmacy,” said: Dr. Patrick Donnelly, Chief Medical Officer, NorthStar Medical Radioisotopes. “The RadioGenix System will enable us to provide Purdue students with the opportunity to gain hands-on experience with the latest advancements in nuclear pharmacy.”

The Purdue College of Pharmacy is providing NorthStar with feedback about the RadioGenix System and early testing of planned enhancements.

About the Purdue University College of Pharmacy

For almost 135 years, the Purdue College of Pharmacy has trained the world’s elite pharmacy leaders through acclaimed curricula, preeminent faculty and active industry partnerships. The College produces elite pharmacy leaders who are improving lives worldwide in rewarding, top-paying healthcare careers. The Purdue College of Pharmacy is consistently ranked among the top pharmacy programs in the nation.

About the RadioGenix® System

The RadioGenix System is an innovative, high tech separation platform that is approved for processing non-uranium/non-highly enriched uranium molybdenum-99 (Mo-99) for the production of the important medical radioisotope, technetium-99m (Tc-99m). Prior to availability of RadioGenix technology, the U.S. supply chain for Mo-99 has been subject to frequent and sometimes severe interruptions which negatively impact patient healthcare. Approved by the U.S. Food and Drug Administration in 2018, the RadioGenix System is the first and only on-site, automated isotope separation system of its kind for use with non-uranium/non-highly enriched uranium based Mo-99, designed to help alleviate shortage situations and expand domestic supply.

The RadioGenix® System is a technetium Tc-99m generator used to produce Sodium Pertechnetate Tc 99m Injection, USP. Sodium Pertechnetate Tc 99m Injection is a radioactive diagnostic agent and can be used in the preparation of FDA-approved diagnostic radiopharmaceuticals.

Sodium Pertechnetate Tc 99m Injection is also indicated in

- Adults for Salivary Gland Imaging and Nasolacrimal Drainage System Imaging (dacryoscintigraphy).
- Adults and pediatric patients for Thyroid Imaging and Vescoureteral Imaging (direct isotopic cystography) for detection of vescoureteral reflux.
Allergic reactions (skin rash, hives, or itching) including anaphylaxis have been reported following the administration of Sodium Pertechnetate Tc 99m Injection. Monitor all patients for hypersensitivity reactions.

Radiation risks associated with the use of Sodium Pertechnetate Tc 99m Injection are greater in children than in adults and, in general, the younger the child, the greater the risk owing to greater absorbed radiation doses and longer life expectancy. These greater risks should be taken firmly into account in all benefit-risk assessments involving children. Long-term cumulative radiation exposure may be associated with an increased risk of cancer.

Temporarily discontinue breastfeeding. A lactating woman should pump and discard breastmilk for 12 to 24 hours after Sodium Pertechnetate Tc 99m Injection administration.

Sodium Pertechnetate Tc 99m Injection should be given to pregnant women only if the expected benefits to be gained clearly outweigh the potential hazards.

Only use potassium molybdate Mo-99, processing reagents, saline and other supplies, including kits, provided by NorthStar Medical Radioisotopes. Do not administer Sodium Pertechnetate Tc 99m Injection after the 0.15 microCi of Mo-99/mCi of Tc-99m limit has been reached or when the 12 hour expiration time from elution is reached, whichever occurs earlier.


NorthStar Medical Radioisotopes is a nuclear medicine technology company committed to providing the United States with reliable and environmentally friendly radioisotope supply solutions to meet the needs of patients and to advance clinical research. The Company’s first product is the RadioGenix® System, an innovative and flexible platform technology initially approved by the U.S. Food and Drug Administration in February 2018 for the processing of non-uranium/non-highly enriched uranium based molybdenum-99 (Mo-99), the parent isotope of technetium-99m (Tc-99m), which is currently the most widely used diagnostic radioisotope for medical purposes. NorthStar’s proprietary and patented technologies include non-uranium based molybdenum-99 domestic production methods, patented separation chemistry systems, patented sterilization systems and a technology platform that potentially allows expanded product offerings to provide solutions in both the diagnostic and therapeutic markets. Founded in 2006 and based in Beloit, Wis., NorthStar Medical Radioisotopes, LLC is a wholly-owned subsidiary of NorthStar Medical Technologies, LLC. For more information, visit: [www.northstarnm.com](http://www.northstarnm.com).

For NorthStar Medical Radioisotopes, LLC

Corporate:

Lisa Holst

Vice President Sales and Marketing

678-471-9027
Purdue University College of Pharmacy and NorthStar Medical Radioisotopes Announce Collaborative Agreement Expanding Nuclear Pharmacy Training Curriculum

Published on Purdue College of Pharmacy (https://www.pharmacy.purdue.edu)

lholst@northstarnm.com

---

Priscilla Harlan
781-799-7917
pharlan@shiningrockllc.com

___

Maria Munoz, Communications Manager
765-496-0525
munoz28@purdue.edu